echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Jisi Yingda ERK kinase inhibitor was approved for clinical use

    Jisi Yingda ERK kinase inhibitor was approved for clinical use

    • Last Update: 2021-09-05
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On August 16, JSI Indah announced that it had received the "Clinical Trial Notice" approved and issued by the National Medical Products Administration, and its extracellular regulated kinase (ERK) inhibitor JSI-1187 capsule was approved for treatment A clinical trial of patients with advanced solid tumors with mutations in the MAPK signaling pathway


    The ERK signaling pathway plays a key role in tumorigenesis and the regulation of key cell processes such as cell cycle progression, cell proliferation, migration, survival, differentiation, aging, metabolism, protein synthesis and angiogenesis


    In addition, abnormal activation of the ERK pathway is also common in the secondary resistance of BRAF, MEK, KRAS, ALK, CDK4/6, TRKA and EGFR inhibitors that have been marketed


    JSI-1187 is an oral, highly selective ERK1 and ERK2 small molecule kinase inhibitor independently developed by JSI.


    Note: The original text has been deleted

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.